文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

高危细胞遗传学对接受CD19靶向CAR T细胞治疗的儿童和年轻成人结局的影响

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
PubMed 文献 · Blood · 2022-01-01

该研究纳入2012年4月至2019年4月在5项CD19靶向CAR T细胞临床试验中接受CTL019或人源化CART19治疗,或接受商业替沙基奥仑赛的231例1至29岁复发/难治性CD19+急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者,按细胞遗传学分层。总体完全缓解率为94%,各层间无差异;高危组2年无复发生存率为63%(95%CI 52-77),2年总生存率为70%(95%CI 60-82),各层间无差异。

要点

  • 高危细胞遗传学组2年无复发生存率为63%(95%CI 52-77),2年总生存率为70%(95%CI 60-82)。
  • 各细胞遗传学分层间完全缓解率、无复发生存率和总生存率均无显著差异(RFS P=0.8112,OS P=0.5488)。
  • KMT2A重排婴儿ALL患者(n=13)2年无复发生存率为67%(95%CI 45-99),2年总生存率为62%(95%CI 40-95)。

核心结论

  • CTL019/人源化CART19/替沙基奥仑赛在各细胞遗传学类别中均能有效实现持久缓解。
  • 包括KMT2A重排婴儿ALL在内的高危细胞遗传学复发/难治性患者,在2年时表现出较高的无复发生存率和总生存率概率。

研究设计与样本

  • 研究识别了2012年4月至2019年4月在5项CD19靶向CAR T细胞(CTL019或人源化CART19)临床试验中接受治疗,或接受商业替沙基奥仑赛治疗的复发/难治性CD19+急性淋巴细胞白血病/淋巴母细胞淋巴瘤儿童和年轻成人患者。
  • 共纳入231例年龄1至29岁的患者,按白血病细胞遗传学分层:高危定义为KMT2A(MLL)重排、费城染色体(Ph+)、Ph样、低二倍体或TCF3/HLF;有利定义为高二倍体或ETV6/RUNX1;中间定义为iAMP21、IKZF1缺失或TCF3/PBX1。
  • 231例患者中,74例(32%)为高危,28例(12%)为中间,43例(19%)为有利,86例(37%)为无法归类。

主要发现

  • 总体完全缓解率为94%,各分层间无差异。
  • 无复发生存率(RFS)无差异(P=0.8112),高危组2年RFS为63%(95%CI 52-77)。
  • 总生存率(OS)同样无差异(P=0.5488),高危组2年OS为70%(95%CI 60-82)。
  • KMT2A重排婴儿ALL患者(n=13)2年RFS为67%(95%CI 45-99),2年OS为62%(95%CI 40-95)。
  • 多变量分析显示KMT2A重排婴儿ALL患者复发风险未增加(风险比0.70;95%CI 0.21-2.90;P=0.7040),但髓系谱系转换相关复发比例更高,全因死亡风险增加3.6倍(95%CI 1.04-12.75;P=0.0434)。

关键数值与推荐

  • 高危细胞遗传学定义:KMT2A(MLL)重排、费城染色体(Ph+)、Ph样、低二倍体或TCF3/HLF。
  • 有利细胞遗传学定义:高二倍体或ETV6/RUNX1。
  • 中间细胞遗传学定义:iAMP21、IKZF1缺失或TCF3/PBX1。
  • KMT2A重排婴儿ALL患者多变量分析:复发风险比0.70(95%CI 0.21-2.90;P=0.7040),全因死亡风险比3.6(95%CI 1.04-12.75;P=0.0434)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested differential outcomes mediated by leukemia cytogenetics. We identified children and young adults with relapsed/refractory CD19+ ALL/lymphoblastic lymphoma treated on 5 CD19-directed CAR T-cell (CTL019 or humanized CART19) clinical trials or with commercial tisagenlecleucel from April 2012 to April 2019. Patients were hierarchically categorized according to leukemia cytogenetics: High-risk lesions were defined as KMT2A (MLL) rearrangements, Philadelphia chromosome (Ph+), Ph-like, hypodiploidy, or TCF3/HLF; favorable as hyperdiploidy or ETV6/RUNX1; and intermediate as iAMP21, IKZF1 deletion, or TCF3/PBX1. Of 231 patients aged 1 to 29, 74 (32%) were categorized as high risk, 28 (12%) as intermediate, 43 (19%) as favorable, and 86 (37%) as uninformative. Overall complete remission rate was 94%, with no difference between strata. There was no difference in relapse-free survival (RFS; P = .8112), with 2-year RFS for the high-risk group of 63% (95% confidence interval [CI], 52-77). There was similarly no difference seen in overall survival (OS) (P = .5488), with 2-year OS for the high-risk group of 70% (95% CI, 60-82). For patients with KMT2A-rearranged infant ALL (n = 13), 2-year RFS was 67% (95% CI, 45-99), and OS was 62% (95% CI, 40-95), with multivariable analysis demonstrating no increased risk of relapse (hazard ratio, 0.70; 95% CI, 0.21-2.90; P = .7040) but a higher proportion of relapses associated with myeloid lineage switch and a 3.6-fold increased risk of all-cause death (95% CI, 1.04-12.75; P = .0434). CTL019/huCART19/tisagenlecleucel are effective at achieving durable remissions across cytogenetic categories. Relapsed/refractory patients with high-risk cytogenetics, including KMT2A-rearranged infant ALL, demonstrated high RFS and OS probabilities at 2 years.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leahy AB, Devine KJ, Li Y, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022. PMID: 34871373. doi:10.1182/blood.2021012727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。